ROLE OF THE KNOWN MUCOLYTICS IN MUCOVISCIDOSIS THERAPY
https://doi.org/10.15690/pf.v11i6.1224
Abstract
The primary objective in the mucoviscidosis therapy is to ensure normal rheology of respiratory secretion for effective evacuation
thereof from the bronchial tree and nasal sinuses. Enzyme drug dornase alfa features the best evidence base for effectiveness and safety of use to treat mucoviscidosis among mucolytics; it rapidly transforms thick viscous sputum into liquid secretion. Along with that, numerous studies have confirmed anti-inflammatory and antibacterial effects thereof: the enzyme breaks down biofilm of the mucoid Pseudomonas aeruginosa, thus reducing volume of the destructive component in pulmonary tissue in the event of an inflammation; it is capable of decreasing concentration of neutrophil elastase and interleukin 8 in sputum, as well as of matrix metal proteinases in bronchoalveolar lavage. Continuous intake of this drug in combination with kinesitherapy and other baseline drugs ensures the patient’s well-being, lower rate of bronchopulmonary process exacerbations, reduction in the hospital admission rate and significant improvement of the quality of life.
About the Authors
O. I. Simonova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
Yu. V. Gorinova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Shak S., Capon D.J., Hellmiss R., Marsters S.A., Baker C.L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. USA: Proceedings of the National Academy of Science. 1990; 87: 9188−9192.
2. Lieberman J. Enzymatic dissolution of pulmonary secretions. American Journal of Diseases of Children. 1962; 104: 342–348.
3. McCarty M. Purification and properties of deoxyribonuclease isolated from beef pancreas. Journal of General Physiology. 1946; 29: 123–139.
4. Armstrong J.B., White J.C. Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet. 1950; 2: 739–742.
5. Chernick W.S., Barbero G.J., Eichel H.J. In vitro evaluation of effect of enzymes on tracheobronchial secretions from patients with cystic fibrosis. Pediatrics. 1961; 27: 589–596.
6. Chernick W.S., Barbero G.J. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiecstasis. Pediatrics. 1959; 24: 739–745.
7. Potter J., Matthews L.W., Lemm J., Spector S. The composition of pulmonary secretions from patients with and without cystic fibrosis. American Journal of Diseases of Children. 1960; 100: 493–495.
8. Matthews L.W., Spector S., Lemm J., Potter J.L. The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis and laryngectomy. American Review of Respiratory Diseases. 1963; 88: 199–204.
9. Cimonova O.I., Solov'eva Yu.V., Vasil'eva E.M. Mucolytics with anti-inflammatory properties for children with cystic fibrosis: dornase alfa. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (6): 85–90.
10. Simonova O.I., Lukina O.F. Dornase alfa: three clinical effect. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2008; 5 (2): 26–32.
11. Shah P., Conwey S., Scott S., Hodson M. A case-controlled study with Dornase Alfa to evaluate impact on disease progression over a 4 year period. J Respiration. 2001; 68: 160–164.
12. Voronkova A.Yu. Klinicheskaya effektivnost' i bezopasnost' dornazy al'fa v lechenii bronkholegochnogo protsessa u detei, bol'nykh mukovistsidozom. Avtoref. dis. …kand. med. nauk [Clinical Efficacy and Safety of Dornase Alfa in the Treatment of Bronchopulmonary Process in Children with Cystic Fibrosis. Author’s abstract]. Moscow, 2004. P. 23.
13. Rosenstein B.J., Johnson C.A.C. et al. Long-term follow-up of Phase III rhDNase trial. Pediatric Pulmonology. 1994; 10 (Suppl.): 113–114.
14. Green J.D. Pharmacological-toxicological expert report on recombinant human deoxyribonuclease I (rhDNase; PulmozymeR). Human and Experimental Toxicology. 1994; 13 (Suppl. 1): S1–S42.
15. Shah P.L., Scott S.F., Geddes D.M., Hodson M.E. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respiratory Medicine. 1995; 89: 499–502.
16. Kearney C.E., Wallis C.E. Deoxyribonuclease for cystic fibrosis: Cochrane Review. In: The Cochrane Library, Issue 3. Oxford: Update Software. 2002.
17. Simonova O.I., Lukina O.F. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2008; 5 (2): 26–32.
18. Amin R., Subbarao P., Lou W., Jabar A., Balkovec S. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J. 2011; 37: 806–812.
19. Verhaeghe C., Delbecque K., de Leval L. et al. Early inflammation in the airways of a cystic fibrosis foetus. J Cyst Fibros. 2007; 6 (4): 304–08.
20. Berger M., Sorensen R.U., Tosi M.F. Complement receptor expression on neutrophilsat an inflammatory site the pseudomonas infected lung in cystic fibrosis. J Clin Invest.1989; 84: 1303–13.
21. Mc Kensi S., Chowdhury S., Strandvik B., Hodson M.E. Dornase alfa is well toleranted: data from the epidemiologic registry of CF. Pediatr Puimonol. 2007; 42 (10): 928–937.
22. Nash E., Stephenson A., Ratjen F., Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev. 2009; (1).
23. Kapranov N.I., Gembitskaya T.E., Simonova O.I., Amelina E.L. Experience in long-term use of a new mucolytic drug Pulmozyme in patients with cystic fibrosis. Terapevticheskii arkhiv = Therapeutic archive. 2001; 1: 55–58.
24. Shah P.L., Scott S.F., Fuchs H.J., Geddes D.M., Hodson M.E. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax. 1995; 50 (4): 333–8.
25. Hodson M.E. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis. Am J Respir Crit Care Med. 1995 Mar; 151(3 Pt. 2): S70–4.
26. Zach M.S. The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, many problems. Thorax. 1996; 51 (7): 750–5.
27. Bakker E.M., Tiddens H.A. Pharmacology, clinical efficacy and safety of recombinant human DNase in cystic fibrosis. Expert Rev Respir Med. 2007 Dec; 1 (3): 317–29.
28. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., Rosenstein B.J., Smith A.L., Wohl M.E. For the Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with Cystic Fibrosis. N Engl J Med. 1994; 331: 637–642.
29. Hubbard R.C., McElvaney N.G., Birrer P., Shak S., Robinson W.W., Jolley C., Wu M., Chernick M.S., Crystal R.G. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992 Mar 19; 326 (12): 812–5.
30. Aitken M.L., Burke W., McDonald G., Shak S., Montgomery A.B., Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA. 1992 Apr 8; 267 (14): 1947–51.
31. Quan J.M., Tiddens H.A.W.M., Sy J.P. et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis and mild lung function abnormalities. Journal of Pediatrics. 2001; 139: 813–820.
32. Shah P.L., Scott S.F., Geddes D.M. et al. An evaluation of two aerosol delivery systems for rhDNase. European Respiratory Journal. 1997; 10: 1261–1266.
33. Fiel S.B., Fuchs H.J., Johnson C. et al. Comparison of three jet nebuliser aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. Chest. 1995; 108: 153–156.
34. Mainz J.G., Koitchev A. Management of chronic rhinosinusitis in cystic fibrosis. J Cystic Fibrosis. 2009; 8: 10–14.
35. Ushakova S.G., Belavina P.I., Simonova O.I., Karneeva O.V. A new method of conservative treatment of chronic rhinosinusitis in children with cystic fibrosis. Voprosy sovremennoi pediatrii = Current Pediatrics. 2010; 9 (5): 72–79.
36. Mainz J.G., Mentzel H.J., Schneider G. et al. Sinu-nasalinhalation of dornase alfa in CF. Results of a double-blind placebocontrolled pilot trial. J Cystic Fibrosis. 2008; 7: 27.
37. Jones A.P., Wallis C.E. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2010; 3.
38. Boat T.F. Cystic Fibrosis. In: Textbook of Respiratory Medicine, J.F. Murray, J.A. Nadel (eds). Saunders WB, Philadelphia. 1988; 1: 1126–1152.
39. Smyth A.R., Bell S.C., Bojcin S., Bryon M., Duff A., Flume P., Kashirskaya N.J. et al. Review. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis. 2014; 13: S23–42.
40. Heijerman H., Westerman E., Conway S., Touw D. Gerd Döring for the consensus working group 1. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. Journal of Cystic Fibrosis. 2009; 8: 295–315.
41. Wark P., McDonald V.M. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2009; 2.
42. Mogayzel P.J., Naureckas E.T., Robinson K.A., Mueller G., Hadjiliadis D., Hoag J.B. et al. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med. 2013; 187: 680–9.
43. Suri R., Metcalfe C., Wallis C., Bush A. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol. 2004; 37: 305–310.
44. Amin R., Subbarao P., Jabar A., Balkovec S., Jensen R. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax. 2010; 65: 379–383.
45. Furnari M.L., Termini L., Traverso G., Barrale S., Bonaccorso M.R. Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized double-blind, controlled study. Ther Adv Respir Dis. 2012; 6: 315.
46. Singer F., Stanojevic S., Yammine S., Subbarao P., Jensen R. Effects of dornase alfa and hypertonic saline on gas mixing in lung periphery in children with cystic fibrosis. Abstracts of ERS International Congress. Eur Resp Journal. 2014; 44 (Suppl.): 58.
47. Bilton D., Robinson P., Cooper P., Gallagher C.G., Kolbe J., Fox H. et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J. 2011; 38: 1071–80.
48. Aitken M.L., Bellon G., De Boeck K., Flume P.A., Fox H.G., Geller D.E. et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012; 185: 645–52.
49. Bilton D., Bellon G., Charlton B., Cooper P., De Boeck K., Flume P.A. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. Journal of Cystic Fibrosis. 2013; 12: 367–376.
50. Amelina E. L., Anaev E.Kh., Krasovskii S. A., Romanova L. K., Simonova O. I., Chernyaev A. L., Chikina S. Yu. Mukoaktivnaya terapiya. Pod red. Chuchalina A.G., Belevskogo A.S. [Mucoactive Therapy. Edited by Chuchalina A.G., Belevskii A.S.]. Moscow, Izdatel'skii dom «Atmosfera», 2006. 104–124 p.
51. Mukovistsidoz. Pod red. N. I. Kapranova, N. Yu. Kashirskoi [Cystic Fibrosis. Edited by N.I. Kapranov, N.Yu. Kashirskaya]. Moscow, Medpraktika-M, 2014. P. 426–427.
52. Grasemann H., Stehling F., Brunar H., Widmann R., Laliberte T.W., Molina L. et all. Inhalation of Moli1901 in patients with CF. Chest. 2007; 131: 1461–1466.
Review
For citations:
Simonova O.I., Gorinova Yu.V. ROLE OF THE KNOWN MUCOLYTICS IN MUCOVISCIDOSIS THERAPY. Pediatric pharmacology. 2014;11(6):96-103. (In Russ.) https://doi.org/10.15690/pf.v11i6.1224
Views:
1016
Email this article 